--- title: Predictors of Rupture Risk of Intracranial Aneurysms nct_id: NCT04613427 overall_status: COMPLETED sponsor: University of Bergen study_type: OBSERVATIONAL primary_condition: Subarachnoid Hemorrhage, Aneurysmal countries: Norway canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04613427.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04613427" ct_last_update_post_date: 2020-11-03 last_seen_at: "2026-05-12T07:02:57.385Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Predictors of Rupture Risk of Intracranial Aneurysms **Official Title:** Predictors of Rupture Risk of Intracranial Aneurysms - Impact of Lipid Metabolism and Mitochondrial Function **NCT ID:** [NCT04613427](https://clinicaltrials.gov/study/NCT04613427) ## Key Facts - **Status:** COMPLETED - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 60 - **Lead Sponsor:** University of Bergen - **Conditions:** Subarachnoid Hemorrhage, Aneurysmal, Intracranial Aneurysm - **Start Date:** 2018-04-01 - **Completion Date:** 2019-06-21 - **CT.gov Last Update:** 2020-11-03 ## Brief Summary Patients admitted to Haukeland University Hospital with either UIA or aSAH underwent a measurement of bioelectrical impedance and body mass composition using InBody 10. Lipids and lipoproteins were collected from plasma. 60 patients in total were included in the study. ## Detailed Description Subarachnoid hemorrhage (SAH) is a condition mainly caused by the rupture of intracranial aneurysms. The estimated prevalence of intracranial aneurysms in the general population is 1-2%, with an annual incidence of aneurysm rupture causing subarachnoid hemorrhage estimated around 1% in Norway. The mortality rates for aneurysmal subarachnoid hemorrhage (aSAH) are as high as 35%, and for the survivors the condition represents a significant morbidity with long-term cognitive impairment and other challenges. With a mean age of 51-55 years at presentation, the burden, both for the patients themselves and on health care resources, is substantial. Thus, the risk assessment and management of patients with unruptured intracranial aneurysms (UIA) represents a substantial challenge. The number of patients with incidentally discovered cerebral aneurysms is rapidly growing with the increasing use of non-invasive intracranial magnetic resonance imaging (MRI). Therapy options are endovascular coiling, neurosurgical clipping, or observation. To decide whether to perform a potentially harmful prophylactic procedure or not, better tools to predict the risk of rupture in the given individual are required. Some risk factors, both for the development of an intracranial aneurysm and for the rupture leading to hemorrhage are identified, such as hypertension, age and smoking. Recent research has shown that obesity and hypercholesterolemia is surprisingly associated with an apparent lower risk of aSAH. However, underlying body composition and dyslipidemic patterns has not yet been explored. Increased knowledge of predictors for aneurysm rupture is required, both to improve the patient care and the decision-making concerning the neurosurgical prevention of aSAH. In the RAPID project, the investigators aim to identify potential new risk factors for the rupture of intracranial aneurysms by comparing the lipid and lipoprotein profile and the body mass composition in patients with UIA and aSAH. Direct-segmental multisegmental bioimpedance analysis (DSM-BIA) is a valid tool for the assessment of total body and segmental composition and has shown excellent agreements when compared with dual energy X-ray absorptiometry (DEXA). Body composition will be analysed within day 2 after intervention or surgery using a DSM-BIA scanner (InBody S10, BioSpace Ltd, Seoul, South Korea). Lipids will be measured enzymatically in ethylenediaminetetraacetic acid (EDTA) plasma/serum on a Hitachi 917 system (Roche Diagnostics GmbH, Mannheim, Germany) using the triacylglycerol (GPO-PAP), cholesterol (CHOD-PAP), HDL-cholesterol plus and LDL-cholesterol plus kit from Roche Diagnostics, and the non-esterifies fatty acid (NEFA FD) kit and the phospholipids kit (Phospholipids FS) from "DiaSys Diagnostic Systems GmbH" (Holzheim, Germany). Glucose will be measured in EDTA-plasma using the Gluco-quant Glucose/HK (GLU) kit from Roche. The total fatty acid composition in EDTA-plasma will be analysed using gas chromatography/mass spectrometry (GC/MS). Lipoprotein particle size analysis will be performed by proton nuclear magnetic resonance (NMR) spectroscopy. Particle concentrations of lipoproteins of different sizes will be calculated from the measured amplitudes of their spectroscopically lipid methyl group NMR signals. Lipoprotein particle size will be derived from the sum of diameter of each subclass multiplied by its relative mass percentage based on the amplitude of its methyl NMR signal. Particle size analysis will be performed by the Norwegian University of Science and Technology (NTNU). ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Admitted electively for treatment of unruptured intracranial aneurysm * Admitted acutely for aneurysmal subarachnoid hemorrhage * Informed consent form signed by patient or close relative Exclusion Criteria: * Pregnant * Pacemaker * Subarachnoid hemorrhage without identified aneurysmal rupture * Unruptured aneurysm with previous SAH/intracranial hemorrhage ``` ## Arms - **Unruptured intracranial aneurysm** — Patients admitted at Haukeland University Hospital in the study period for treatment of UIA. - **Aneurysmal subarachnoid hemorrhage** — Patients admitted at Haukeland University Hospital in the study period for treatment of aSAH. ## Primary Outcomes - **Anthropometric risk factors of ruptured versus unruptured intracranial aneurysms** _(time frame: The anthropometric data will be collected within 96 hours after admittance, as well as information on the predictors and risk factors from the patient journal.)_ — The case group with SAH patients will be compared to the control group with UIA patients. The anthropometric variables is measured by InBody S10 and includes BMI, waist circumference, visceral fat area, body fat mass, body fat percentage, fat free mass, and skeletal muscle mass. The waist/height ratio will be calculated. The data will be analyzed by generalized linear modeling (logistic regression), and the models will be controlled for prognostic factors, including sex, age, hypertension, smoking, alcoholism, statin use, family history of SAH, aneurysm size, diabetes, and cardiovascular disease. ## Secondary Outcomes - **Standard lipid risk factors of ruptured versus unruptured intracranial aneurysms** _(time frame: Blood samples collection within 96 hours after admittance. Calculations will be performed within 3 years after study completion (June 2022).)_ - **Lipid ratios as risk factors of ruptured versus unruptured intracranial aneurysms** _(time frame: The calculations will be performed prior to statistical analyses within 3 years after study completion (June 2022).)_ - **Apolipoprotein risk factors of ruptured versus unruptured intracranial aneurysms** _(time frame: Blood samples collection within 96 hours after admittance.)_ - **Apolipoprotein A1/B ratio as a risk factor of ruptured versus unruptured intracranial aneurysms** _(time frame: Calculations will be performed within 3 years after study completion (June 2022).)_ - **Lipoprotein subclass risk factors of ruptured versus unruptured intracranial aneurysms.** _(time frame: Blood samples collection within 96 hours after admittance.)_ ## Locations (1) - University of Bergen, Bergen, Hordaland, Norway ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.university of bergen|bergen|hordaland|norway` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04613427.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04613427* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*